Published in Trials on August 12, 2010
A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med (2012) 4.51
Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale: analysis of putative high-risk features from the risk of paradoxical embolism database. Circ Cardiovasc Imaging (2013) 2.56
An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology (2013) 2.26
Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ (2015) 2.10
Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med (2011) 1.92
What is the evidence for physical therapy poststroke? A systematic review and meta-analysis. PLoS One (2014) 1.87
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care (2013) 1.71
Clinical Prediction Models for Cardiovascular Disease: Tufts Predictive Analytics and Comparative Effectiveness Clinical Prediction Model Database. Circ Cardiovasc Qual Outcomes (2015) 1.62
Personalised medicine: not just in our genes. BMJ (2012) 1.51
Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials (2011) 1.49
A framework for crafting clinical practice guidelines that are relevant to the care and management of people with multimorbidity. J Gen Intern Med (2014) 1.46
A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials. Clin Pharmacol Ther (2013) 1.45
Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses. BMJ (2016) 1.41
Three simple rules to ensure reasonably credible subgroup analyses. BMJ (2015) 1.40
Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ (2011) 1.32
Conceptual, methodological, and ethical problems in communicating uncertainty in clinical evidence. Med Care Res Rev (2012) 1.28
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer (2015) 1.28
Multimorbidity and evidence generation. J Gen Intern Med (2014) 1.17
Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. J Clin Epidemiol (2013) 1.14
Random treatment assignment using mathematical equipoise for comparative effectiveness trials. Clin Transl Sci (2011) 1.14
Cardiovascular risk and statin use in the United States. Ann Fam Med (2014) 1.13
Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines. Circ Cardiovasc Qual Outcomes (2011) 1.11
Using internally developed risk models to assess heterogeneity in treatment effects in clinical trials. Circ Cardiovasc Qual Outcomes (2014) 1.07
Using evidence to combat overdiagnosis and overtreatment: evaluating treatments, tests, and disease definitions in the time of too much. PLoS Med (2014) 1.04
Achieving the "triple aim" for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence framework. Genet Med (2012) 1.04
From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primer. BMC Med Res Methodol (2012) 1.03
A systematic review on the development of asthma and allergic diseases in relation to international immigration: the leading role of the environment confirmed. PLoS One (2014) 1.02
Building useful evidence: changing the clinical research paradigm to account for comparative effectiveness research. J Comp Eff Res (2012) 1.01
How well do randomized trials inform decision making: systematic review using comparative effectiveness research measures on acupuncture for back pain. PLoS One (2012) 0.97
A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. J Clin Epidemiol (2013) 0.94
Individualized cost-effectiveness analysis. PLoS Med (2011) 0.92
Moneyball, gambling, and the new cholesterol guidelines. Circ Cardiovasc Qual Outcomes (2014) 0.90
Prediction of responders for outcome measures of locomotor Experience Applied Post Stroke trial. J Rehabil Res Dev (2014) 0.89
Effect of inborn vs. outborn delivery on neurodevelopmental outcomes in infants with hypoxic-ischemic encephalopathy: secondary analyses of the NICHD whole-body cooling trial. Pediatr Res (2012) 0.88
Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol (2013) 0.88
Individual differences and evidence-based psychopharmacology. BMC Med (2012) 0.86
Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder. Epidemiol Psychiatr Sci (2016) 0.84
Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol (2016) 0.84
Tight glycemic control after pediatric cardiac surgery in high-risk patient populations: a secondary analysis of the safe pediatric euglycemia after cardiac surgery trial. Circulation (2014) 0.82
Conceptual and Analytical Considerations toward the Use of Patient-Reported Outcomes in Personalized Medicine. Am Health Drug Benefits (2012) 0.82
Caring for patients with kidney disease: shifting the paradigm from evidence-based medicine to patient-centered care. Nephrol Dial Transplant (2015) 0.81
Co-prescription trends in a large cohort of subjects predict substantial drug-drug interactions. PLoS One (2015) 0.81
Reporting guidelines: optimal use in preventive medicine and public health. Am J Prev Med (2012) 0.81
Mixing nulliparous and multiparous women in randomised controlled trials of preeclampsia prevention is debatable: evidence from a systematic review. PLoS One (2013) 0.80
Reply: Comment on 'Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'. Br J Cancer (2015) 0.80
Limitations of medical research and evidence at the patient-clinician encounter scale. Chest (2013) 0.79
Racial variation in the cost-effectiveness of chemotherapy for prostate cancer. J Oncol Pract (2011) 0.78
Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. J Transl Med (2015) 0.78
Empirical Treatment Effectiveness Models for Binary Outcomes. Med Decis Making (2015) 0.77
Towards personalised intra-arterial treatment of patients with acute ischaemic stroke: a study protocol for development and validation of a clinical decision aid. BMJ Open (2017) 0.77
Field Synopsis of the Role of Sex in Stroke Prediction Models. J Am Heart Assoc (2016) 0.77
Indomethacin for post-endoscopic retrograde cholangiopancreatography pancreatitis prophylaxis: is it the magic bullet? World J Gastroenterol (2012) 0.77
Treatment matching for obesity: identifying mediators of psychosocial and behavioral intervention components. Int J Obes Suppl (2012) 0.76
Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes. BMC Med Res Methodol (2016) 0.76
Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia (BPH). BJU Int (2014) 0.75
A predictive model to identify patients with suspected acute coronary syndromes at high risk of cardiac arrest or in-hospital mortality: An IMMEDIATE Trial sub-study(,,.) Int J Cardiol Heart Vasc (2015) 0.75
Individualizing endpoints in randomized clinical trials to better inform individual patient care: the TARGET proposal. Crit Care (2016) 0.75
No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals. Trials (2016) 0.75
A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res (2014) 0.75
Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention. Am Heart J (2016) 0.75
The "Dry-Run" Analysis: A Method for Evaluating Risk Scores for Confounding Control. Am J Epidemiol (2017) 0.75
LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. Diabetol Metab Syndr (2016) 0.75
Managing physician lipid management: a population wide, risk-based decision support approach. Isr J Health Policy Res (2015) 0.75
An approach to addressing subpopulation considerations in systematic reviews: the experience of reviewers supporting the U.S. Preventive Services Task Force. Syst Rev (2017) 0.75
A systematic approach to designing statistically powerful heteroscedastic 2 × 2 factorial studies while minimizing financial costs. BMC Med Res Methodol (2016) 0.75
Separating signal from noise: the challenge of identifying useful biomarkers in sepsis. Crit Care (2014) 0.75
An Interoperable Similarity-based Cohort Identification Method Using the OMOP Common Data Model version 5.0. J Healthc Inform Res (2017) 0.75
Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges. J Vet Intern Med (2017) 0.75
Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models. Med Decis Making (2017) 0.75
Prophylaxis of pancreatitis with intravenous ketoprofen in a consecutive population of ERCP patients: a randomized double-blind placebo-controlled trial. Surg Endosc (2016) 0.75
Why most published research findings are false. PLoS Med (2005) 41.68
Validation of a combined comorbidity index. J Clin Epidemiol (1994) 19.43
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA (2001) 16.98
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA (2000) 12.86
Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med (2007) 12.55
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet (1994) 11.37
Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet (2000) 9.80
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med (2001) 9.31
Adjusting for multiple testing--when and how? J Clin Epidemiol (2001) 8.85
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med (2005) 8.55
Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med (2002) 7.41
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
A consumer's guide to subgroup analyses. Ann Intern Med (1992) 6.34
Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA (1991) 6.05
Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet (2005) 5.94
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.86
Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA (2007) 5.60
Assessment of claims of improved prediction beyond the Framingham risk score. JAMA (2009) 5.36
An evidence based approach to individualising treatment. BMJ (1995) 5.10
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation (2004) 4.45
Moderators of treatment outcomes: clinical, research, and policy importance. JAMA (2006) 4.03
Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol (2004) 3.93
West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet (1996) 3.85
Problems in the "evidence" of "evidence-based medicine". Am J Med (1997) 3.85
Can overall results of clinical trials be applied to all patients? Lancet (1995) 3.69
Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q (2004) 3.60
Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest (2006) 3.54
Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ (2010) 3.54
Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol (2002) 3.36
Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess (2001) 3.32
Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Intern Med (2009) 3.14
Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. European Carotid Surgery Trialists' Collaborative Group. Lancet (1999) 3.05
Practical guidelines for multiplicity adjustment in clinical trials. Control Clin Trials (2000) 2.67
Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation (2008) 2.45
Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol (2006) 2.27
Optimal management of acute coronary syndromes. N Engl J Med (2009) 2.10
Heterogeneity is not always noise: lessons from improvement. JAMA (2009) 2.04
Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2. Ann Intern Med (1998) 2.01
Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol (2007) 2.00
Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet (2005) 1.96
A framework for tailoring clinical guidelines to comorbidity at the point of care. Arch Intern Med (2007) 1.92
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J (2002) 1.73
Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer (2007) 1.68
The limitations of evidence. J R Coll Physicians Lond (1998) 1.67
False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons. J Natl Cancer Inst (1996) 1.66
Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med (2007) 1.62
Reporting clinical trial results to inform providers, payers, and consumers. Health Aff (Millwood) (2005) 1.57
Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading? Am Heart J (2006) 1.48
The impact of high-risk patients on the results of clinical trials. J Clin Epidemiol (1997) 1.46
Dealing with heterogeneity of treatment effects: is the literature up to the challenge? Trials (2009) 1.44
Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? Stroke (2003) 1.36
Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. Am Heart J (2000) 1.20
Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation (2005) 1.14
What makes a good predictor?: the evidence applied to coronary artery calcium score. JAMA (2010) 1.13
Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. Am J Epidemiol (1998) 1.05
Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulin-dependent) diabetes mellitus? Diabetologia (2000) 1.04
Competing risk and heterogeneity of treatment effect in clinical trials. Trials (2008) 1.01
Comparison of mortality benefit of immediate thrombolytic therapy versus delayed primary angioplasty for acute myocardial infarction. Am J Cardiol (2007) 1.01
Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data. J Clin Epidemiol (2001) 0.97
More on subgroup analyses in clinical trials. N Engl J Med (2008) 0.96
Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. Am Heart J (1997) 0.94
Assessing treatment effect heterogeneity in clinical trials with blocked binary outcomes. Biom J (2005) 0.92
A percutaneous coronary intervention-thrombolytic predictive instrument to assist choosing between immediate thrombolytic therapy versus delayed primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol (2008) 0.89
A multivariate test of interaction for use in clinical trials. Biometrics (1999) 0.87
What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experience. Circulation (1983) 0.86
Evidence based medicine: concerns of a clinical neurologist. J Neurol Neurosurg Psychiatry (2001) 0.85
The 'number need to treat': does it help clinical decision making? J Hum Hypertens (1999) 0.82
Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet (2008) 30.94
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (2009) 22.18
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med (2009) 21.74
Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci (2013) 13.37
Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One (2008) 13.32
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med (2009) 12.16
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol (2009) 11.80
The case of the misleading funnel plot. BMJ (2006) 8.26
Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet (2007) 7.27
Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ (2014) 7.21
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet (2007) 7.11
Comparison of quality of care for patients in the Veterans Health Administration and patients in a national sample. Ann Intern Med (2004) 6.86
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 6.80
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet (2008) 6.71
Duration of resuscitation efforts and survival after in-hospital cardiac arrest: an observational study. Lancet (2012) 6.60
Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol (2007) 6.15
Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol (2008) 5.88
Research grants: Conform and be funded. Nature (2012) 5.83
Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA (2002) 5.81
Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA (2007) 5.60
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Assessment of claims of improved prediction beyond the Framingham risk score. JAMA (2009) 5.36
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet (2009) 5.32
Why current publication practices may distort science. PLoS Med (2008) 5.09
The relative importance of physician communication, participatory decision making, and patient understanding in diabetes self-management. J Gen Intern Med (2002) 4.79
Evaluation of networks of randomized trials. Stat Methods Med Res (2007) 4.70
Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol (2009) 4.60
Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet (2003) 4.58
Number of published systematic reviews and global burden of disease: database analysis. BMJ (2003) 4.53
A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med (2012) 4.51
The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med (2015) 4.49
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst (2005) 4.48
Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol (2005) 4.45
Public availability of published research data in high-impact journals. PLoS One (2011) 4.41
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Relative citation impact of various study designs in the health sciences. JAMA (2005) 4.19
Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ (2012) 4.16
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol (2010) 4.10
Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet (2010) 4.06
The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol (2010) 4.04
Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol (2012) 3.93
Methods for meta-analysis in genetic association studies: a review of their potential and pitfalls. Hum Genet (2007) 3.92
Predicting death: an empirical evaluation of predictive tools for mortality. Arch Intern Med (2011) 3.81
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med (2003) 3.81
Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med (2012) 3.79
Relation between burden of disease and randomised evidence in sub-Saharan Africa: survey of research. BMJ (2002) 3.78
Translation of highly promising basic science research into clinical applications. Am J Med (2003) 3.74
Lessons from the mammography wars. N Engl J Med (2010) 3.68
Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med (2012) 3.63
Overlapping meta-analyses on the same topic: survey of published studies. BMJ (2013) 3.57
Empirical evaluation of very large treatment effects of medical interventions. JAMA (2012) 3.48
Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. Lancet (2012) 3.48
Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst (2005) 3.41
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat Genet (2012) 3.40
Meta-analysis in genome-wide association studies. Pharmacogenomics (2009) 3.39
Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol (2012) 3.37
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol (2004) 3.28
Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol (2007) 3.19
Medicine. Life cycle of translational research for medical interventions. Science (2008) 3.12
Are bad outcomes from questionable clinical decisions preventable medical errors? A case of cascade iatrogenesis. Ann Intern Med (2002) 3.07
Mechanisms for racial and ethnic disparities in glycemic control in middle-aged and older Americans in the health and retirement study. Arch Intern Med (2007) 3.05
Carotid artery stenosis: accuracy of noninvasive tests--individual patient data meta-analysis. Radiology (2009) 2.94
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst (2006) 2.91
Racial disparities in diabetes care processes, outcomes, and treatment intensity. Med Care (2003) 2.88
Addition of brain and carotid imaging to the ABCD² score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study. Lancet Neurol (2010) 2.87
Patients, privacy and trust: patients' willingness to allow researchers to access their medical records. Soc Sci Med (2006) 2.86
Building a better quality measure: are some patients with 'poor quality' actually getting good care? Med Care (2003) 2.85
National Stroke Association guidelines for the management of transient ischemic attacks. Ann Neurol (2006) 2.82
HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics (2005) 2.81
Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med (2009) 2.80
Accepting critically ill transfer patients: adverse effect on a referral center's outcome and benchmark measures. Ann Intern Med (2003) 2.75
The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med (2006) 2.74
Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med (2004) 2.73
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med (2015) 2.71
Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol (2013) 2.70
Whom should we profile? Examining diabetes care practice variation among primary care providers, provider groups, and health care facilities. Health Serv Res (2002) 2.68
Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics (2004) 2.60
Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol (2005) 2.59
Meta-analysis methods for genome-wide association studies and beyond. Nat Rev Genet (2013) 2.58
Reporting and interpretation of SF-36 outcomes in randomised trials: systematic review. BMJ (2009) 2.57
Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev (2013) 2.56
Timing of birth and risk of multiple sclerosis: population based study. BMJ (2004) 2.56
Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ (2013) 2.52
Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA (2008) 2.52
Effects of interventions on survival in acute respiratory distress syndrome: an umbrella review of 159 published randomized trials and 29 meta-analyses. Intensive Care Med (2014) 2.51
Origin and funding of the most frequently cited papers in medicine: database analysis. BMJ (2006) 2.47
Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand. Arthritis Rheum (2009) 2.47
Claims of sex differences: an empirical assessment in genetic associations. JAMA (2007) 2.46
Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer (2007) 2.46
Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation (2008) 2.45
Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. J Clin Epidemiol (2009) 2.45
Systematic evaluation of environmental factors: persistent pollutants and nutrients correlated with serum lipid levels. Int J Epidemiol (2012) 2.42
Sources of funding for Nobel Prize-winning work: public or private? FASEB J (2010) 2.42
Case management for patients with poorly controlled diabetes: a randomized trial. Am J Med (2004) 2.41
Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ (2006) 2.40
STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med (2009) 2.39